Researchers at Lund University in Sweden have discovered a possible reason why leukemia cells, particularly in acute myeloid leukemia (AML), evade the immune system, offering a potential pathway to improve immunotherapy for this hard-to-treat cancer. The findings, detailed in a recent press release, highlight a mechanism that could explain the limited success of immunotherapies in AML compared to other cancers.
Immunotherapy has achieved significant success in treating various cancers by harnessing the body's immune system to target and destroy cancer cells. However, its effectiveness in AML has been disappointing. The Lund University team identified a specific factor that allows leukemia cells to avoid immune detection and destruction. The researchers plan to further develop an antibody targeting this mechanism and conduct clinical trials aimed at moving their discovery toward regulatory approval.
This breakthrough comes as other companies, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), are also exploring innovative approaches to cancer treatment, including the use of oncolytic viruses and stem cell-based therapies. The Lund University discovery could complement these efforts by providing a new target for immunotherapy in leukemia.
The study's implications are significant, as AML is an aggressive cancer with a low survival rate, especially in older patients. Current treatments often involve intensive chemotherapy, which can be toxic and is not always effective. Immunotherapies that can specifically target leukemia cells while sparing healthy cells could offer a more tolerable and effective treatment option.
The researchers are now working on refining their antibody and hope to begin clinical trials soon. If successful, this could lead to a new class of immunotherapies for AML and potentially other blood cancers. The findings also underscore the importance of understanding the unique immune evasion strategies employed by different cancers, which is critical for developing personalized treatment approaches.
This discovery was reported by BioMedWire, a platform covering developments in the biotechnology and life sciences sectors. The full terms of use and disclaimers for BioMedWire content are available on their website.
